全国代表性样本中物质使用障碍的强与弱交叉遗传
研究基于美国全国代表性样本NESARC-III(n=36,309),以外显子组芯片检测363,496个SNP,比较酒精、尼古丁、大麻及非医疗处方阿片类使用障碍与3959名「超级对照」的遗传重叠。多基因评分在12,505名欧洲 ancestry 个体中计算,显示酒精与尼古丁使用障碍存在强交叉遗传,而阿片类使用障碍遗传具有独特性。
要点
- 酒精使用障碍与尼古丁使用障碍存在强交叉遗传。
- 阿片类使用障碍的遗传具有独特性。
- 多基因评分揭示各物质使用障碍共享与非共享的遗传贡献。
核心结论
- 基于多基因评分的发现强调物质使用障碍发病机制中共享与非共享的遗传贡献,证实酒精与尼古丁使用障碍的强交叉遗传以及阿片类使用障碍遗传的独特性。
研究设计与样本
- 研究采用外显子组聚焦的基因分型,在美国全国代表性样本NESARC-III(n=36,309)中分析四种物质使用障碍的交叉遗传。
- 所有诊断基于面对面结构化精神科访谈(AUDADIS-5)。
- 物质使用障碍病例单独及合并与3959名「超级对照」(无物质使用障碍且无精神障碍)比较,使用外显子组聚焦芯片检测363,496个SNP。
- 多基因评分在样本的欧洲 ancestry 部分(n=12,505)中计算,使用四种临床不同物质使用障碍各自与3959名「超级对照」比较的汇总统计。
主要发现
- 酒精使用障碍(AUD)n=4487,尼古丁使用障碍(NUD)n=4394,大麻使用障碍(CUD)n=954,非医疗处方阿片类使用障碍(NMPOUD)n=346。
- 一种或多种物质使用障碍的29个顶级易感基因与既往GWAS of SUD所提示的基因高度重叠。
- 多基因评分用于预测物质使用障碍严重程度(轻度、中度或重度)以及预测其他3种物质使用障碍。
关键数值与推荐
- 所有诊断基于AUDADIS-5面对面结构化精神科访谈。
- 「超级对照」定义为既无物质使用障碍也无精神障碍,共3959名。
- 芯片检测363,496个SNP。
- 多基因评分在n=12,505的欧洲 ancestry 样本中计算。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Substance use disorders (SUDs) are moderately to highly heritable and are in part cross-transmitted genetically, as observed in twin and family studies. We performed exome-focused genotyping to examine the cross-transmission of four SUDs: alcohol use disorder (AUD, n = 4487); nicotine use disorder (NUD, n = 4394); cannabis use disorder (CUD, n = 954); and nonmedical prescription opioid use disorder (NMPOUD, n = 346) within a large nationally representative sample (n = 36,309), the National Epidemiologic Survey on Alcohol and Related Conditions-III (NESARC-III). All diagnoses were based on in-person structured psychiatric interview (AUDADIS-5). SUD cases were compared alone and together to 3959 "super controls" who had neither a SUD nor a psychiatric disorder using an exome-focused array assaying 363,496 SNPs, yielding a representative view of within-disorder and cross-disorder genetic influences on SUDs. The 29 top susceptibility genes for one or more SUDs overlapped highly with genes previously implicated by GWAS of SUD. Polygenic scores (PGS) were computed within the European ancestry (EA) component of the sample (n = 12,505) using summary statistics from each of four clinically distinct SUDs compared to the 3959 "super controls" but then used for two distinctly different purposes: to predict SUD severity (mild, moderate, or severe) and to predict each of the other 3 SUDs. Our findings based on PGS highlight shared and unshared genetic contributions to the pathogenesis of SUDs, confirming the strong cross-inheritance of AUD and NUD as well as the distinctiveness of inheritance of opioid use disorder.
引用
- Zhang H, Grant BF, Hodgkinson CA, et al. Strong and weak cross-inheritance of substance use disorders in a nationally representative sample. Mol Psychiatry. 2021. PMID: 34759357. doi:10.1038/s41380-021-01370-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。